



## Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

February 28, 2019

WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast, for Thursday, March 7, 2019. The schedule for the press release and conference call/webcast are as follows:

- Q4 2018 Press Release: March 7, 2019 at 4:00 p.m. ET
- Q4 2018 Conference Call: March 7, 2019 at 4:30 p.m. ET
- Domestic Dial-In Number: 1-866-393-1607
- International Dial-In Number: 1-914-495-8556
- Conference ID Number: 1942769

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com).

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-855-859-2056 or 1-404-537-3406, and reference conference ID 1942769.

### About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors

Mark Murray  
President and CEO  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

#### Media

Pam Murphy  
Investor Relations Consultant  
Phone: 604-419-3200  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)



Source: Arbutus Biopharma Corporation